Yiling Pharmaceutical signs new agreement for 2017 raised funds oversight

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Yiling Pharmaceutical) announced the signing of a three-party supervisory agreement for its raised funds. This agreement follows the company's decision to open a new dedicated bank account at China CITIC Bank, Shijiazhuang Branch, for the temporary replenishment of working capital from its 2017 non-public offering. The company’s eighth board of directors approved this resolution on August 27, 2025.

The dedicated account, with account number 8111801012601380960, had a balance of CNY 0 as of September 28, 2025. It is exclusively for the storage and use of funds allocated to supplement working capital and may not be used for other purposes. This setup ensures that the funds, originally totaling CNY 1,288,808,798.84 after expenses from the 2017 issuance, are managed in accordance with regulatory requirements.

China International Capital Corporation Limited (CICC), as the sponsor, will supervise the use of these funds, conducting regular checks and investigations. The agreement, effective from the date of signing by all parties, will remain valid until all funds are expended and the account is legally closed.